Table 1 Demographics, classification and treatment variables
Characteristics | Complete dataset (n = 142) | PAH (n = 90) | PAH with comorbidities (n = 52) | p-value |
|---|---|---|---|---|
n (%) | n (%) | n (%) | ||
Female sex no. [%] | 87 (61.3) | 66 (73.3%) | 21 (40.4%) | < 0.0001 |
Diagnostic group of PAH [%] | ||||
IPAH | 44 (31%) | 44 (48.8%) | ||
HPAH | 4 (2.8%) | 4 (4.4%) | ||
DPAH | 1 (0.7%) | 1 (1.1%) | ||
APAH | 41 (28.9%) | 41 (45.6%) | ||
PAH with cardiac comorbidities | 33 (23.3%) | 33 (63.5%) | ||
PAH with pulmonary comorbidities | 19 (13.4%) | 19 (36.5%) | ||
Group of APAH [%] | ||||
Connective tissue diseases | 37 (26.1%) | 37 (41.1%) | ||
HIV | 1 (2.5%) | 1 (1.1%) | ||
Portal hypertension | 3 (0.7%) | 3 (3.3%) | ||
No. of PAH drugs | 0.82 | |||
Monotherapy | 90 (63.4%) | 56 (62.2%) | 34 (65.4%) | |
Double combination | 50 (35.2%) | 33 (36.7%) | 17 (32.7%) | |
Triple combination | 2 (1.4%) | 1 (1.1%) | 1 (1.9%) | |
Type of PAH drug at diagnosis [%] | 0.02 | |||
Calcium channel blocker | 12 (8.5%) | 4 (4.4%) | 8 (15.4%) | |
Endothelin receptor antagonist | 62 (43.7%) | 48 (53.3%) | 14 (26.9%) | |
Phosphodiesterase 5 inhibitor | 108 (76.1%) | 65 (72.2%) | 43 (82.7%) | |
Prostacyclin | 2 (1.4%) | 1 (1.1%) | 1 (1.9%) | |
Soluble guanylate cyclase stimulator | 7 (4.9%) | 3 (3.3%) | 4 (7.7%) | |
Oxygen treatment | 53 (37.3%) | 25 (27.8%) | 28 (53.8%) | |
Anticoagulants | 116 (81.7%) | 69 (76.7%) | 47 (90.4%) | 0.042 |
Diuretics | 108 (76.1%) | 63 (70.0%) | 45 (86.5%) | 0.026 |